Sundyota Numandis

What Sundyota Numandis does

Sundyota Numandis is an India-based, founder-led natural therapeutics company founded in 2003 and headquartered in Ahmedabad. The company develops, in-licenses, manufactures, and markets probiotics, nutraceuticals, and phytopharmaceutical products across ten therapeutic categories—women's health, pediatric care, respiratory, bone and joint, pain and inflammation, gut health, neuro health, cosmo-derma, dental, and metabolic—for prescription and recommendation by physicians, and more recently direct to consumers.

The portfolio includes 40+ branded products such as Microbac GG (a MicroBac-technology probiotic backed by 50+ clinical trials), EPs Pelargin (an antiviral/antibacterial with 25+ clinical trials), India's first strain-specific postbiotic products (Lp-33, Scalpbiome, AAP-2, Ps flora), and condition-specific formulations spanning bacterial vaginosis, PCOS, allergic rhinitis, IBS, osteoarthritis, and depression. Manufacturing is conducted at a cGMP-compliant, 80,000 sq. ft Ahmedabad facility with Class D clean rooms, capacity for 1 billion hard capsules, 425 million tablets, 1.8 million kg of powder blends, and 10 million liquid bottles annually. The facility holds FSSAI Schedule IV, Food cGMP, FSSC 22000 Version 6, and US FDA Registered Facility certifications.

Revenue is generated through four channels: (1) B2B in-licensing and supply via Sundyota Numandis Probioceuticals (est. 2012); (2) physician-promoted B2C sales of in-licensed molecules in India, operating since 2010; (3) direct-to-consumer sales via Sundyota Lifecare (launched 2020); and (4) international B2B and private-label/contract manufacturing via Sundyota Numandis Schweiz GmbH in Switzerland (est. 2020). A 14+ partner global in-licensing network spanning Iceland, Spain, Belgium, Italy, France, Switzerland, India, Taiwan, and Germany supplies distinct therapeutic IP, while in-house fermentation-based R&D is operated through Sundyota Numandis Biosciences (est. 2023). Pricing is quote-based and not publicly disclosed; the company is privately held with no external equity investors identified.

Name

Sundyota Numandis

Legal name

Sundyota Numandis

Website

https://sundyotanumandis.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Sundyota Numandis is an Ahmedabad-based, founder-led natural therapeutics company (founded 2003) that develops, in-licenses, and manufactures probiotics, nutraceuticals, and phytopharmaceutical products across ten therapeutic categories, serving physicians, B2B partners, and direct-to-consumer markets in 20+ countries.

Ownership category

akta.pro rank

Product category

Nutraceutical and Phytopharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Eye, Ear & Nasal Care OTC (Eye Drops, Ear Drops/Wax Removal, Saline Sprays) (CRADAMAG)

akta.pro secondary industry

OTC Medicines & Consumer Health Products Distribution (CRAOAHAB)

Keywords

• Probiotic supplements
• Nutraceutical manufacturing
• Phytopharmaceutical products
• Contract manufacturing
• Natural therapeutics

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. B2B Product Sales & In-Licensing: Sundyota Numandis Probioceuticals (B2B arm established 2012) generates revenue through research, in-licensing, development, manufacturing, and marketing of clinically proven products. Revenue comes from proprietary and in-licensed probiotic, nutraceutical, and phytopharmaceutical products sold to other businesses and healthcare institutions.
2. Contract Manufacturing & Private Label: Sundyota Numandis Schweiz provides private label and contract manufacturing of high-end food supplements to global customers, generating revenue through manufacturing fees and product supply.
3. B2C In-Licensed Product Sales: B2C promotion of exclusively in-licensed molecules targeting physicians and key opinion leaders in India, generating product sales revenue.
4. Direct-to-Consumer Sales: Sundyota Lifecare (D2C vertical launched 2020) generates revenue through direct consumer sales of health products.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels1 record

Core offering

Sundyota Numandis researches, develops, manufactures, and markets clinically validated probiotic, nutraceutical, and phytopharmaceutical products. The company in-licenses proprietary molecules from global partners, manufactures them at a cGMP-compliant facility in Ahmedabad, and distributes them through B2B channels (in-licensing, private label, contract manufacturing) and direct-to-consumer channels (Sundyota Lifecare) across 20+ countries.

Product overview

Sundyota Numandis operates as a diversified natural therapeutics company with multiple business divisions and a comprehensive product portfolio. The company offers nutraceuticals, probiotics (non-spore), and phyto-pharmaceuticals through various business verticals including Sundyota Numandis Probioceuticals (B2B), Sundyota Numandis Research & Formulations, Sundyota Numandis Biosciences (fermentation-based R&D), Sundyota Lifecare (D2C), and Sundyota Numandis Schweiz GmbH (international B2B/private label). The product portfolio spans 40+ branded products organized across 10 therapeutic categories: Women's Health (VAC, Ova-Flora, V-Flora, Tradfertil, GD-Flora, Endoaid, Rheum rhaponticum Extract, Meno-IsoCal), Paediatric Care (Microbac GG, EPs Pelargin, Lp-33, Bifibaby GG, Bifiobese), Respiratory Health (Respipro), Bone & Joint Health (Collavant n2, Boscocal JC, Tendaxion, Ligaheal, Ogenic Elements, Boscurin Nucleo, Celements Recovery, ch-OSA), Pain & Inflammation (Boscurin, Beta-Caryophyllene, Cal Myrrh), Gut Health (Microbac GG, SB Glabra, Bifidobacterium longum W11 + FOS, Bifidobacterium lactis BS 01, Procovery), Neuro Health (Celements Nucleo, Cal Myrrh Combination, Lactium + L-theanine + Melatonin, Cerebiome, Recovery), Cosmo Derma (AAP-2, Lp-6, ch-OSA, OraGlo, Scalpbiome, Ps flora), Dental Health (ADP-1, SMF Lyco, ch-OSA), and Metabolic Health (Naturolive HT, Probiotics for Diabetes, Merastin). Manufacturing capabilities include hard capsules (1B/year), powders (1.8M kg/year), tablets (425M/year), and oral liquids (10M bottles/year), with cGMP-compliant facilities in Ahmedabad.

Differentiator

Problem solved

Functional benefit

Products and services

• VAC Standardised composition indicated for PMS, mastalgia, and menstrual cycle irregularity. Targeted at women's health therapeutic area.
• Ova-Flora Synergistic combination of probiotics and VAC for effective management of various symptoms associated with PCOS. Targeted at women's health.
• V-Flora Tailor-made supplementation as per Indian vaginal flora, indicated for bacterial vaginosis and yeast candidiasis. Targeted at women's health.
• Tradfertil Clinically proven formula which acts beyond antioxidants for OAT and IOAT cases of infertility, indicated for male infertility.
• GD-Flora Clinically studied combination of probiotics indicated for women with gestational diabetes.
• Endoaid Synergistic formulation for reducing pelvic pain, dysmenorrhea, and dyspareunia, indicated for endometriosis.
• Rheum rhaponticum Extract Clinically proven SERM for peri-menopausal and menopausal symptom management.
• Meno-IsoCal Formula beyond soy isoflavones paired with VAC extract to manage osteoporosis and other symptoms in post-menopausal women.
• Microbac GG World's most researched probiotic with MicroBac technology for gut health, backed by 50+ clinical trials, safe to use in infants. Indicated for acute watery diarrhoea and NEC.
• EPs Pelargin Fast acting antiviral, antibacterial, secretolytic, and immunomodulator backed by 25+ clinical trials. Indicated for common cold, bronchitis, acute bacterial rhinosinusitis, and as add-on in COPD.
• Lp-33 India's first strain-specific postbiotic for reduction in symptoms of allergies, indicated for allergic rhinitis.
• Bifibaby GG Synergistic formulation of clinically studied probiotics along with dill oil and fennel oil, indicated for colic pain.
• Bifiobese

Quantifiable outcome

• 50+ clinical trials backing MicroBac probiotic technology for gut health
• +3 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

14 partnerships are on record, tiered core.

• Iceland PartnercoreStrategic or Co-development PartnerLeading producer and supplier of products based on microalgae as well as fermentation. Sundyota Numandis collaborates with this partner for advanced fermentation-based products and microalgae-derived ingredients.
• Spain Partner 1 (Nutraceuticals & Probiotics)coreStrategic or Co-development PartnerA prominent name in advanced and most refined nutraceuticals and probiotics. Partnership enables access to cutting-edge natural health formulations.
• Spain Partner 2 (Joint & Tendon Care)coreStrategic or Co-development PartnerGlobal leaders in research and development of bio-molecules for joint and tendon care. Collaboration supports bone and joint health product portfolio.
• Belgium PartnercoreStrategic or Co-development PartnerA globally prominent name in skin, nail, hair and bone health. Partnership contributes to cosmo-derma and skeletal health product lines.
• Italy PartnercoreStrategic or Co-development PartnerDerives clinically proven ingredients from eggs (egg-shell membrane) for joint & tendon care and cosmetology. Provides unique ingredient source for collagen-based products.
• France PartnercoreStrategic or Co-development PartnerAn academic, research based organization having phytopharmaceutical extracts with highly concentrated bioactive molecules. Supports advanced phytopharmaceutical product development.
• Switzerland Partner 1 (Men's Health)coreStrategic or Co-development PartnerSpecializes in a wide range of products for men's sexual health. Expands product portfolio into men's health therapeutic area.
• Switzerland Partner 2 (Probiotics)coreStrategic or Co-development PartnerA world leader in technologically advanced, strain specific probiotics and pharmabiotics. Provides access to cutting-edge probiotic technologies.
• India Partner 1 (Phytopharmaceuticals)coreStrategic or Co-development PartnerA leading name in R&D of phytopharmaceuticals, with over 300 patented botanical extracts. Major source of botanical IP and formulation expertise.
• India Partner 2 (Stress Management)coreStrategic or Co-development PartnerA world leader in nutritional ingredients and supplements, specializing in stress management. Supports neuro health and wellness product lines.
• Taiwan PartnercoreStrategic or Co-development PartnerA renowned name in R&D of advanced probiotics and biotechnology products. Provides probiotic and biotech formulation capabilities.
• Germany Partner 1 (Phytopharmaceuticals)coreStrategic or Co-development PartnerA prominent name in phytopharmaceuticals and nutraceuticals, specializing in women's and children's health. Supports women's health and pediatric product portfolios.
• Germany Partner 2 (Probiotic Strains)coreStrategic or Co-development PartnerA leading company that manufactures specialized probiotic strains. Provides access to proprietary probiotic strains.
• Germany Partner 3 (Olive Extracts)coreStrategic or Co-development PartnerSpecializes in identifying and offering qualitative olive extracts and Phyto-antioxidants. Supports metabolic health and antioxidant product lines.

Scale indicators10 records

Recent moves13 records

Expansion highlights6 records

Direct peers

• BioGaia: Swedish probiotics specialist with clinically documented Lactobacillus reuteri strains sold globally through partner distribution. Highly comparable to Sundyota's MicroBac/strain-specific probiotic business model, with similar focus on physician-channel marketing and clinical substantiation as a differentiator.
• Unique Biotech: India-based probiotic and nutraceutical manufacturer with strong clinical research focus and global exports. Closely matches Sundyota's Indian manufacturing base, probiotic technology orientation, and B2B export business model.
• Morepen Laboratories: Indian pharma and nutraceutical manufacturer with significant API and finished dosage form production. Comparable in scale, manufacturing capabilities, and Indian market positioning to Sundyota, though with a heavier API focus.
• Sabinsa: US-India based manufacturer and supplier of standardized botanical extracts and nutraceutical ingredients, with patented extracts and clinical research focus. Closely comparable to Sundyota's phytopharmaceutical business and Indian partner's 300+ patented botanical extract portfolio.
• Lallemand Health Solutions: Global probiotic and yeast-based ingredient supplier with proprietary strains and clinical research programs. Comparable as a strain-specific probiotic technology provider and partner/supplier in the same value chain where Sundyota competes and sources.

Broad incumbents

• Chr. Hansen (now Novonesis): Global microbial and probiotic ingredient powerhouse serving nutraceutical, dairy, and pharma customers. Comparable as a supplier/incumbent in the strain-specific probiotic space where Sundyota competes, with overlapping technology capabilities and broader scale.
• Dr. Reddy's Laboratories: Large Indian pharmaceutical company with nutraceuticals and consumer health divisions. Comparable as a broader Indian player with overlapping nutraceutical/probiotic ambitions, though much larger and with deeper regulatory expertise than Sundyota.
• Herbalife Nutrition: Global nutrition and weight management company with extensive nutraceutical portfolio and MLM distribution. Comparable as a global nutraceutical incumbent, though with a fundamentally different go-to-market model (direct selling) than Sundyota's physician channel.
• Amway: Global direct-selling company with substantial nutrition and wellness product portfolio including probiotics and botanical supplements. Comparable as a major global nutraceutical incumbent, with overlap in phytopharmaceutical and probiotic categories.
• Danone Nutricia: Global food and nutrition major with a dedicated probiotics and medical nutrition portfolio. Comparable in probiotic science and global distribution reach, with much broader resources and brand recognition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/sundyota-numandis
• Xx.com/SDNCorporate
• Facebookfacebook.com/about

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sundyota Numandis